SCM
DMAC icon

Sterling Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Sterling Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4K Hold
206
– – ﹤0.01% 3046
2025
Q4 		$1.64K Buy
206
+129
+168% +$965 ﹤0.01% 3089
2025
Q3 		$529 Buy
77
+13
+20% +$71 ﹤0.01% 3151
2025
Q2 		$250 Buy
+64
New +$250 ﹤0.01% 3221

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sterling Capital Management's DMAC Position: Q1 2026 in Review

Sterling Capital Management held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 206 shares worth $1.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3046.

Sterling Capital Management first reported a position in DMAC in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.64K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Sterling Capital Management held 206 shares of DiaMedica Therapeutics worth $1.4K as of Q1 2026.
  • Sterling Capital Management left its DiaMedica Therapeutics share count unchanged in Q1 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3046 holding.
  • Sterling Capital Management first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Sterling Capital Management's DiaMedica Therapeutics position peaked at $1.64K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.